Efficacy of CHK inhibitors as single agents in MYC-driven lymphoma cells

Oncogene

Volumn 31, Issue 13, 2012, Pages 1661-1672

  Ferrao, P T ^a,b   Bukczynska, E P ^a   Johnstone, R W ^a,b   McArthur, G A ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

CHK inhibitors; DNA damage; E myc; p19ARF; p53

Indexed keywords

ANTINEOPLASTIC AGENT; ARF PROTEIN; AZD 7762; CASPASE; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; CHECKPOINT KINASE INHIBITOR; MYC PROTEIN; PF 0477736; PROTEIN P19; PROTEIN P53; PROTEIN SERINE THREONINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CELL DEATH; CELL SURVIVAL; CONTROLLED STUDY; DNA DAMAGE; DNA REPLICATION; DRUG EFFICACY; ENZYME INHIBITION; GENE EXPRESSION; LYMPHOMA; LYMPHOMA CELL; MOUSE; NONHUMAN; NULL ALLELE; ONCOGENE C MYC; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; WILD TYPE;

ANIMALS; APOPTOSIS; BENZODIAZEPINONES; CASPASES; CELL LINE, TUMOR; DNA DAMAGE; GENES, MYC; GENES, P53; HUMANS; LYMPHOMA; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASM TRANSPLANTATION; PROTEIN KINASES; PYRAZOLES;

EID: 84859428543     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.358     Document Type: Article

References (50)

1. Abulaiti A, Fikaris AJ, Tsygankova OM, Meinkoth JL. (2006). Ras induces chromosome instability and abrogation of the DNA damage response. Cancer Res 66: 10505-10512. (Pubitemid 44799772)
2. Adams JM, Harris AW, Pinkert CA, Corcoran LM, Alexander WS, Cory S et al. (1985). The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 318: 533-538. (Pubitemid 16173038)
3. Ashwell S, Zabludoff S. (2008). DNA damage detection and repair pathways-recent advances with inhibitors of checkpoint kinases in cancer therapy. Clin Cancer Res 14: 4032-4037.
4. Bartek J, Bartkova J, Lukas J. (2007). DNA damage signalling guards against activated oncogenes and tumour progression. Oncogene 26: 7773-7779. (Pubitemid 350242463)
5. Bartek J, Lukas J. (2003). Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 3: 421-429. (Pubitemid 38340288)
6. Bartkova J, Horejsi Z, Koed K, Kramer A, Tort F, Zieger K et al. (2005). DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434: 864-870. (Pubitemid 40558993)
7. Bartkova J, Rezaei N, Liontos M, Karakaidos P, Kletsas D, Issaeva N et al. (2006). Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 444: 633-637. (Pubitemid 44864442)
8. Bertwistle D, Sherr CJ. (2007). Regulation of the Arf tumor suppressor in Em-Myc transgenic mice: longitudinal study of Myc-induced lymphomagenesis. Blood 109: 792-794. (Pubitemid 46105983)
9. Blasina A, Hallin J, Chen E, Arango ME, Kraynov E, Register J et al. (2008). Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1. Mol Cancer Ther 7: 2394-2404.
10. Braig M, Lee S, Loddenkemper C, Rudolph C, Peters AH, Schlegelberger B et al. (2005). Oncogene-induced senescence as an initial barrier in lymphoma development. Nature 436: 660-665. (Pubitemid 41117262)
11. Chanoux RA, Yin B, Urtishak KA, Asare A, Bassing CH, Brown EJ. (2009). ATR and H2AX cooperate in maintaining genome stability under replication stress. J Biol Chem 284: 5994-6003.
12. Cole KA, Huggins J, Laquaglia M, Hulderman CE, Russell MR, Bosse K et al. (2011). RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma. Proc Natl Acad Sci U S A 108: 3336-3341.
13. Dai Y, Grant S. (2010). New insights into checkpoint kinase 1 in the DNA damage response signaling network. Clin Cancer Res 16: 376-383.
14. Deans AJ, Khanna KK, McNees CJ, Mercurio C, Heierhorst J, McArthur GA. (2006). Cyclin-dependent kinase 2 functions in normal DNA repair and is a therapeutic target in BRCA1-deficient cancers. Cancer Res 66: 8219-8226. (Pubitemid 44299190)
15. Di Micco R, Fumagalli M, Cicalese A, Piccinin S, Gasparini P, Luise C et al. (2006). Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 444: 638-642. (Pubitemid 44864443)
16. Dominguez-Sola D, Ying CY, Grandori C, Ruggiero L, Chen B, Li M et al. (2007). Non-transcriptional control of DNA replication by c-Myc. Nature 448: 445-451. (Pubitemid 47123512)
17. Eischen CM, Weber JD, Roussel MF, Sherr CJ, Cleveland JL. (1999). Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev 13: 2658-2669. (Pubitemid 29508553)
18. Enders GH. (2008). Expanded roles for Chk1 in genome maintenance. J Biol Chem 283: 17749-17752.
19. Giroux V, Iovanna J, Dagorn JC. (2006). Probing the human kinome for kinases involved in pancreatic cancer cell survival and gemcitabine resistance. FASEB J 20: 1982-1991. (Pubitemid 44953898)
20. Halazonetis TD, Gorgoulis VG, Bartek J. (2008). An oncogene-induced DNA damage model for cancer development. Science 319: 1352-1355. (Pubitemid 351354863)
21. Hickson I, Zhao Y, Richardson CJ, Green SJ, Martin NM, Orr AI et al. (2004). Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res 64: 9152-9159. (Pubitemid 39665530)
22. Janetka JW, Ashwell S, Zabludoff S, Lyne P. (2007). Inhibitors of checkpoint kinases: from discovery to the clinic. Curr Opin Drug Discov Devel 10: 473-486. (Pubitemid 47093131)
23. Kastan MB. (2008). DNA damage responses: mechanisms and roles in human disease: 2007 G.H.A. Clowes Memorial Award Lecture. Mol Cancer Res 6: 517-524.
24. Lindemann RK, Newbold A, Whitecross KF, Cluse LA, Frew AJ, Ellis L et al. (2007). Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma. Proc Natl Acad Sci U S A 104: 8071-8076. (Pubitemid 47185877)
25. Liu Q, Guntuku S, Cui XS, Matsuoka S, Cortez D, Tamai K et al. (2000). Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. Genes Dev 14: 1448-1459. (Pubitemid 30421838)
26. Lord CJ, Ashworth A. (2009). Bringing DNA repair in tumors into focus. Clin Cancer Res 15: 3241-3243.
27. Lotem J, Sachs L. (1993). Hematopoietic cells from mice deficient in wild-type p53 are more resistant to induction of apoptosis by some agents. Blood 82: 1092-1096. (Pubitemid 23253980)
28. Mallette FA, Ferbeyre G. (2007). The DNA damage signaling pathway connects oncogenic stress to cellular senescence. Cell Cycle 6: 1831-1836. (Pubitemid 47327900)
29. Mallette FA, Gaumont-Leclerc MF, Ferbeyre G. (2007). The DNA damage signaling pathway is a critical mediator of oncogene-induced senescence. Genes Dev 21: 43-48. (Pubitemid 46089705)
30. Mercurio C, Pastori S, Crippa R, Alzani R, Albanese M, Muzio M et al. (2004). In vitro and in vivo characterization of the CDK inhibitor PHA-533533. Proc Am Assoc Cancer Res 45: 190.
31. Morgan MA, Parsels LA, Zhao L, Parsels JD, Davis MA, Hassan MC et al. (2010). Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair. Cancer Res 70: 4972-4981.
32. Myers K, Gagou ME, Zuazua-Villar P, Rodriguez R, Meuth M. (2009). ATR and Chk1 suppress a caspase-3-dependent apoptotic response following DNA replication stress. PLoS Genet 5: e1000324.
33. Negrini S, Gorgoulis VG, Halazonetis TD. (2010). Genomic instability - an evolving hallmark of cancer. Nat Rev Mol Cell Biol 11: 220-228.
34. Newbold A, Lindemann RK, Cluse LA, Whitecross KF, Dear AE, Johnstone RW. (2008). Characterisation of the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor romidepsin. Mol Cancer Ther 7: 1066-1079.
35. Nguyen M, Marcellus RC, Roulston A, Watson M, Serfass L, Murthy Madiraju SR et al. (2007). Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc Natl Acad Sci U S A 104: 19512-19517.
36. Parsels LA, Morgan MA, Tanska DM, Parsels JD, Palmer BD, Booth RJ et al. (2009). Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells. Mol Cancer Ther 8: 45-54.
37. R DCT (2009). R: A language and environment for statistical computing. R Foundation for Statistical Computing V: Austria, URLhttp://www.R-project.orgISBN 3-900051-07-0.
38. Redon CE, Nakamura AJ, Zhang YW, Ji JJ, Bonner WM, Kinders RJ et al. (2010). Histone gammaH2AX and poly(ADP-ribose) as clinical pharmacodynamic biomarkers. Clin Cancer Res 16: 4532-4542.
39. Reimann M, Loddenkemper C, Rudolph C, Schildhauer I, Teichmann B, Stein H et al. (2007). The Myc-evoked DNA damage response accounts for treatment resistance in primary lymphomas in vivo. Blood 110: 2996-3004. (Pubitemid 350006954)
40. Reinhardt HC, Aslanian AS, Lees JA, Yaffe MB. (2007). p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage. Cancer Cell 11: 175-189. (Pubitemid 46209849)
41. Schmitt CA, Fridman JS, Yang M, Lee S, Baranov E, Hoffman RM et al. (2002). A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 109: 335-346. (Pubitemid 34606876)
42. Sidi S, Sanda T, Kennedy RD, Hagen AT, Jette CA, Hoffmans R et al. (2008). Chk1 suppresses a caspase-2 apoptotic response to DNA damage that bypasses p53, Bcl-2, and caspase-3. Cell 133: 864-877. (Pubitemid 351715394)
43. Spurr AR. (1969). A low-viscosity epoxy resin embedding medium for electron microscopy. J Ultrastruct Res 26: 31-43.
44. Vafa O, Wade M, Kern S, Beeche M, Pandita TK, Hampton GM et al. (2002). c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability. Mol Cell 9: 1031-1044. (Pubitemid 34626672)
45. Wall M, Poortinga G, Hannan KM, Pearson RB, Hannan RD, McArthur GA. (2008). Translational control of c-MYC by rapamycin promotes terminal myeloid differentiation. Blood 112: 2305-2317.
46. Wilsker D, Petermann E, Helleday T, Bunz F. (2008). Essential function of Chk1 can be uncoupled from DNA damage checkpoint and replication control. Proc Natl Acad Sci USA 105: 20752-20757.
47. Xiao Z, Xue J, Sowin TJ, Zhang H. (2006). Differential roles of checkpoint kinase 1, checkpoint kinase 2, and mitogen-activated protein kinase-activated protein kinase 2 in mediating DNA damage-induced cell cycle arrest: implications for cancer therapy. Mol Cancer Ther 5: 1935-1943. (Pubitemid 44336564)
48. Zabludoff SD, Deng C, Grondine MR, Sheehy AM, Ashwell S, Caleb BL et al. (2008). AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. Mol Cancer Ther 7: 2955-2966.
49. Zenvirt S, Kravchenko-Balasha N, Levitzki A. (2010). Status of p53 in human cancer cells does not predict efficacy of CHK1 kinase inhibitors combined with chemotherapeutic agents. Oncogene 29: 6149-6159.
50. Zhao Y, Thomas HD, BateyMA, Cowell IG, Richardson CJ, Griffin RJ et al. (2006). Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441. Cancer Res 66: 5354-5362. (Pubitemid 43844961)